BioCentury | Jul 17, 2020
Emerging Company Profile

Acepodia: linking antitumor antibodies to immune cells

Acepodia is using its antibody-cell conjugation platform to link tumor-targeting antibodies to the surface of cell therapies while avoiding genetic engineering. The platform, which has the potential for cost savings compared with CAR T therapy,...
BioCentury | Feb 21, 2018
Distillery Therapeutics


INDICATION: Melanoma Cell culture and mouse studies suggest activating or overexpressing NCR2 could help treat melanoma. In a human melanoma cell line, supernatant from NK cells activated by the NCR2 ligand PDGFDD decreased growth compared...
BioCentury | Nov 17, 2016
Product R&D

Hemorrhaging targets

An analysis of the almost 5,000 abstracts set to be presented at the 2016 American Society of Hematology (ASH) meeting next month indicates this year’s hot topics in preclinical research include a spattering of new...
Items per page:
1 - 3 of 3